RAPT Therapeutics’ Lead Drug On Clinical Hold After Case Of Liver Failure

Cause Unknown; May Be Linked To Supplement

 
• By Mandy Jackson

Zelnecirnon (RPT193), in Phase IIb for atopic dermatitis and Phase IIa for asthma, may not have caused the case of liver failure cited in the hold but the pause may impede a crucial data readout.

Face the accumulated contradictions. Blocking further action. Pause and reevaluate the situation.
RAPT's atopic dermatitis trial was halted months before a planned topline readout • Source: Shutterstock

More from Clinical Trials

More from R&D